A Randomized, Double-blind, Phase 3 Study of Vorasidenib Versus Placebo in Patients with Mutant IDH1/2 Diffuse Glioma (INDIGO): Analysis of Health-related Quality of Life, Neurocognition and Seizures (PL5.003)
Katherine B. Peters,Ingo K. Mellinghoff,Martin J. van den Bent,Deborah T. Blumenthal,Mehdi Touat,Jennifer Clarke,Joe Mendez,Shlomit Yust‐Katz,Warren Mason,François Ducray,Yoshie Umemura,Burt Nabors,Matthias Holdhoff,Andreas F. Hottinger,Yoshiki Arakawa,Juan Manuel Sepúlveda-Sánchez,Wolfgang Wick,Riccardo Soffietti,James Perry,Pierre Giglio